摘要
目的:观察不同用药方法治疗哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)的效果。方法:选择2018年2月~2020年5月收治的112例ACOS患者,随机分为Ⅰ组和Ⅱ组各56例,两组均采用沙美特罗替卡松粉吸入剂(商品名:舒利迭)治疗,Ⅱ组加用孟鲁司特钠片,比较两组用药效果。结果:Ⅱ组治疗总有效率为92.9%,高于Ⅰ组的73.2%(P<0.05);治疗后,Ⅱ组患者肺功能(FVC、FEV1)水平更高于同期Ⅰ组,哮喘控制评分更高于Ⅰ组,均有统计学意义(P<0.05);Ⅰ、Ⅱ组不良反应发生率分别为3.6%、5.4%,数据差异不显著(P>0.05)。结论:采用孟鲁司特钠片联合舒利迭医治ACOS,疗效确切,安全性高,值得推广。
Objective: To observe the effect of different medication methods on asthma chronic obstructive pulmonary disease overlap syndrome(ACOS). Methods: 112 patients with ACOS admitted to a hospital from February 2018 to may 2020 were selected and randomly divided into group Ⅰ and group Ⅱ. Both groups were treated with salmeterol fluticasone powder inhalation(trade name: Seretide), and group Ⅱ was treated with montelukast sodium tablets based on the group Ⅰ,then the effects of the two groups were compared. Results:The total effective rate of group Ⅱ was 92.9%, higher than 73.2% of group Ⅰ(P<0.05). After treatment, the level of lung function(FVC, FEV1) in group Ⅱ was higher than that in group Ⅰ, and the asthma control score was higher than that in group Ⅰ,with statistical significance(P<0.05). The incidence of adverse reactions in group Ⅰ and group Ⅱ were 3.6% and 5.4%, respectively, with no significant difference(P>0.05). Conclusion:Montelukast sodium tablets combined with Seretide is effective and safe in the treatment of ACOS, which is worthy of promotion.
作者
史册
李颖
Shi Ce;Li Ying(Department of Respiratory and Critical Care Medicine,First People's Hospital of Shangqiu,Shangqiu,Henan 476100)
出处
《数理医药学杂志》
CAS
2021年第9期1337-1339,共3页
Journal of Mathematical Medicine
